EU approves BMS's Orencia for paediatric arthritis
This article was originally published in Scrip
Executive Summary
The European Commission has approved Bristol-Myers Squibb's Orencia (abatacept) in combination with methotrexate for children with moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) who have had insufficient responses to disease-modifying antirheumatic drugs (DMARDs).